Pneumococcal conjugate vaccine use in adults

References

• Pneumovax® 23 (pneumococcal vaccine polyvalent). Full prescribing information. Whitehouse Station (NJ): Merck & Co., Inc.; 2015.
   Google Scholar
• Centers for Disease Control and Prevention. Pneumococcal disease. CDC Pink Book. 2011;16:233–248.
   Google Scholar
• Andrews NJ, Waight PA, George RC, et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30:6802–6808.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Morb Mortal Wkly Rep. 2012;61:394–395.
   PubMedGoogle Scholar
• Nuorti JP, Whitney CG, Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59:1–18.
   PubMedGoogle Scholar
• Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63:822–825.
   PubMed Web of Science ®Google Scholar
• CBER/FDA. FDA Briefing Document. Prevnar13 (PCV13): pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein). 2011 [cited 2015 Jul 14]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM279681.pdf
   Google Scholar
• Food and Drug Administration. FDA expands use of Prevnar 13 vaccine for people ages 50 and older. 2011 [cited 2014 Aug 18]. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm285431.htm
   Google Scholar
• Amodio E, Costantino C, Boccalini S, et al. Estimating the burden of hospitalization for pneumococcal pneumonia in a general population aged 50 years or older and implications for vaccination strategies. Hum Vaccin Immunother. 2014;10:1337–1342.
   PubMed Web of Science ®Google Scholar
• Fedson DS, Musher DM. Pneumococcal polysaccharide vaccines. In: Plotkin SA, Orenstein JM, editors.. Vaccines. 4th ed. Philadelphia (PA): Saunders Elsevier; 2004.
   Google Scholar
• Fedson DS, Scott JA. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine. 1999;17(Suppl 1):S11–18.
   PubMed Web of Science ®Google Scholar
• Blasi F, Mantero M, Santus P, et al. Understanding the burden of pneumococcal disease in adults. Clin Microbiol Infect. 2012;18(Suppl 5):7–14.
   PubMed Web of Science ®Google Scholar
• Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285:1729–1735.
   PubMed Web of Science ®Google Scholar
• Torres A, Blasi F, Dartois N, et al. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015;70:984–989.
   PubMed Web of Science ®Google Scholar
• Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20(Suppl 5):45–51.
   PubMed Web of Science ®Google Scholar
• Said MA, Johnson HL, Nonyane BA, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One. 2013;8:e60273.
   PubMed Web of Science ®Google Scholar
• Nelson JC, Jackson M, Yu O, et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine. 2008;26:4947–4954.
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179–1186.
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Young-Xu Y, et al. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2011;2:e00309–10.
   PubMed Web of Science ®Google Scholar
• Thomas CP, Ryan M, Chapman JD, et al. Incidence and cost of pneumonia in medicare beneficiaries. Chest. 2012;142:973–981.
   PubMed Web of Science ®Google Scholar
• Sherwin RL, Gray S, Alexander R, et al. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia. J Infect Dis. 2013;208:1813–1820.
   PubMed Web of Science ®Google Scholar
• Yu H, Rubin J, Dunning S, et al. Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population. J Am Geriatr Soc. 2012;60:2137–2143.
   PubMed Web of Science ®Google Scholar
• Weycker D, Strutton D, Edelsberg J, et al. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine. 2010;28:4955–4960.
   PubMed Web of Science ®Google Scholar
• Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011;29:3398–3412.
   PubMed Web of Science ®Google Scholar
• Rello J, Lisboa T, Lujan M, et al. Severity of pneumococcal pneumonia associated with genomic bacterial load. Chest. 2009;136:832–840.
   PubMed Web of Science ®Google Scholar
• Dowell SF. Surviving pneumonia-just a short term lease on life? Am J Respirator Crit Care Med. 2004;169:895–896.
   PubMed Web of Science ®Google Scholar
• Waterer GW, Kessler LA, Wunderink RG. Medium-term survival after hospitalization with community-acquired pneumonia. Am J Respir Crit Care Med. 2004;169:910–914.
   PubMed Web of Science ®Google Scholar
• Corrales-Medina VF, Musher DM, Shachkina S, et al. Acute pneumonia and the cardiovascular system. Lancet. 2013;381:496–505.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816–819.
   PubMedGoogle Scholar
• Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1:ofu024.
   PubMedGoogle Scholar
• Curcio D, Cane A, Isturiz R. Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence. Int J Infect Dis. 2015;37:30–35.
   PubMed Web of Science ®Google Scholar
• Pride MW, Huijts SM, Wu K, et al. Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine. Clin Vaccine Immunol. 2012;19:1131–1141.
   PubMed Web of Science ®Google Scholar
• Bewick T, Sheppard C, Greenwood S, et al. Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia. Thorax. 2012;67:540–545.
   PubMed Web of Science ®Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114–1125.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Welfare. Incidence of invasive pneumococcal disease in Finland. 2015 [cited 2015 Jun 16]. Available from: https://www.thl.fi/en/web/thlfi-en/topics/information-packages/incidence-of-invasive-pneumococcal-disease-in-finland.
   Google Scholar
• Public Health Surveillance. Information for New Zealand public health action. Invasive pneumococcal disease reports. [cited 2015 Jun 2]. Available from: https://surv.esr.cri.nz/surveillance/IPD.php.
   Google Scholar
• Pan American Health Organization. SIREVA II (Sistema de Redes de Vigilancia de los Agentes Responsables do Neumonias y Meningitis Bacterianas). [cited 2015 Jun 9]. Available from: http://www.paho.org/hq/index.php?option=com_content&view=category&layout=blog&id=3609&Itemid=3953.
   Google Scholar
• Lefebvre B. Programme de surveillance du pneumocoque: rapport 2013. 2013 [cited 2015 Jun 9]. Available from: https://www.inspq.qc.ca/pdf/publications/1946_Programme_Surveillance_Pneumocoque.pdf
   Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15:301–309.
   PubMed Web of Science ®Google Scholar
• Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15:535–543.
   PubMed Web of Science ®Google Scholar
• Steens A, Bergsaker MA, Aaberge IS, et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013;31:6232–6238.
   PubMed Web of Science ®Google Scholar
• Instituto de Salad Pública de Chile. Vigilancia de Enfermedad Invasora Streptococcus pneumoniae Chile, 2007–2014. Boletin ISP. 2014;4:1–23.
   Google Scholar
• Pilishvili T, Bennett NM. Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines. Vaccine. 2015;33(Suppl4):D60–D65.
   Web of Science ®Google Scholar
• Pilishvili T. Considerations for pneumococcal 13-valent conjugate and 23-valent polysaccharide vaccine use among adults. Advisory Committee on Immunization Practices. 2014 Aug 13. [cited2015 Dec 1]. Available from: http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2014-08/PCV13-Pilishvili-02.pdf
   Google Scholar
• Stoecker C. Potential public health impact and cost-effectiveness of PCV13 use in adults. Advisory Committee on Immunization Practices (ACIP). Summary Report. 2014 Jun 25–26. [cited 2015 Dec 1]. Available from: http://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2014-06.pdf
   Google Scholar
• Jackson LA, Gurtman A, Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2013;31:3585–3593.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine. 2013;31:3577–3584.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gurtman A, van Cleeff M, et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine. 2013;31:3594–3602.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Schmoele-Thoma B. Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13-valent pneumococcal conjugate vaccine administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged ≥65 years. Vaccine. 2013;31:291–294.
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60–64 years of age. Vaccine. 2014;32:2364–2374.
   PubMed Web of Science ®Google Scholar
• Frenck RW Jr, Gurtman A, Rubino J, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol. 2012;19:1296–1303.
   PubMed Web of Science ®Google Scholar
• Johnson SE, Rubin L, Romero-Steiner S, et al. Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae. J Infect Dis. 1999;180:133–140.
   PubMed Web of Science ®Google Scholar
• Saeland E, Jakobsen H, Ingolfsdottir G, et al. Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B. J Infect Dis. 2001;183:253–260.
   PubMed Web of Science ®Google Scholar
• Bryant KA, Frenck R, Gurtman A, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2015;33:5854–5860.
   PubMed Web of Science ®Google Scholar
• Frenck RW Jr, Fiquet A, Gurtman A, et al. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. Presented at: IDWeek; 2014; Philadelphia, PA.
   Google Scholar
• Grohskopf LA, Olsen SJ, Sokolow LZ, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2014-15 Influenza Season. MMWR Morb Mortal Wkly Rep. 2014;63:691–697.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Flamaing J, Rumke HC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine. 2011;29:5195–5202.
   PubMed Web of Science ®Google Scholar
• Baxter R, Downey HJ, Patterson S, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine coadministered with a quadrivalent influenza vaccine in adults 50 years and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Presented at: 4th Annual Meeting of the Infectious Diseases Society of America; 2015 Oct 7–11; San Diego, CA
   Google Scholar
• Bhorat AE, Madhi SA, Laudat F, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination. Aids. 2015;29:1345–1354.
   PubMed Web of Science ®Google Scholar
• Glesby MJ, Watson W, Brinson C, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults previously vaccinated with pneumococcal polysaccharide vaccine. J Infect Dis. 2014;212:18–27.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Ljungman P, Juergens C, et al. Immunogenicity, safety and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study. Clin Infect Dis. 2015;61:313–323.
   PubMed Web of Science ®Google Scholar
• French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med. 2010;362:812–822.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Pauksens K, Juergens C, et al. Safety of a 13-valent pneumococcal conjugate vaccine in elderly adults previously immunized with a 23-valent pneumococcal polysaccharide vaccine: an open-label trial. World J Vaccine. 2013;3:123–129.
   Google Scholar
• Shiramoto M, Irie S, Juergens C, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years: an open-label trial. Hum Vaccin Immunother. 2014;10:1850–1858.
   PubMed Web of Science ®Google Scholar
• Tinoco JC, Juergens C, Ruiz Palacios GM, et al. Open-label trial of immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults ≥50 years of age in Mexico. Clin Vaccine Immunol. 2015;22:185–192.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Bennett NM, Gierke R, et al. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015;64:944–947.
   PubMed Web of Science ®Google Scholar
• Huss A, Scott P, Stuck AE, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009;180:48–58.
   PubMed Web of Science ®Google Scholar
• Leventer-Roberts M, Feldman BS, Brufman I, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study. Clin Infect Dis. 2015;60:1472–1480.
   PubMed Web of Science ®Google Scholar
• Paradiso PR. Pneumococcal conjugate vaccine for adults: a new paradigm. Clin Infect Dis. 2012;55:259–264.
   PubMed Web of Science ®Google Scholar
• Angoulvant F, Levy C, Grimprel E, et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis. 2014;58:918–924.
   PubMed Web of Science ®Google Scholar
• Becker-Dreps S, Amaya E, Liu L, et al. Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua. Pediatr Infect Dis J. 2014;33:637–642.
   PubMed Web of Science ®Google Scholar
• Berglund A, Ekelund M, Fletcher MA, et al. All-cause pneumonia hospitalizations in children <2 years old in Sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction. PLoS One. 2014;9:e112211.
   PubMed Web of Science ®Google Scholar
• Cohen R, Levy C, Bingen E, et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J. 2012;31:297–301.
   PubMed Web of Science ®Google Scholar
• Dagan R, Patterson S, Juergens C, et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis. 2013;57:952–962.
   PubMed Web of Science ®Google Scholar
• Griffin MR, Mitchel E, Moore MR, et al. Declines in pneumonia hospitalizations of children aged <2 years associated with the use of pneumococcal conjugate vaccines - Tennessee, 1998-2012. MMWR Morb Mortal Wkly Rep. 2014;63:995–998.
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013;32:203–207.
   PubMed Web of Science ®Google Scholar
• Lindstrand A, Bennet R, Galanis I, et al. Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine. Pediatrics. 2014;134:e1528–1536.
   PubMed Web of Science ®Google Scholar
• Moore MR. Update on effectiveness and impact of PCV13 use amoung U.S. children. 2014 [cited 2015 Jan 21]. Available from: http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2014-02/02-Pneumo-Moore.pdf
   Google Scholar
• Simonsen L, Taylor RJ, Schuck-Paim C, et al. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med. 2014;2:387–394.
   PubMed Web of Science ®Google Scholar
• Schuchat A. Pneumococcal prevention gets older and wiser. JAMA Intern Med. 2015;175:1897–1898.
   PubMed Web of Science ®Google Scholar
• Khoie T, Tiernan R, deVore N. FDA Briefing Document. Prenar 13 (PCV13): pneumococcal 13-valent conjugate vaccine (Diphtheria CRM197 Protein). Applicant: Wyeth Pharmaceuticals Inc. 2011 [cited 2015 Nov 3]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM279681.pdf
   Google Scholar
• Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59:1102–1106.
   PubMedGoogle Scholar
• Schmoele-Thoma B, Jackson LA, Greenberg RN, et al. Immunogenicity of 13-valent pneumococcal conjugate vaccine in immunocompetent older adults with stable underlying medical conditions. J Vaccines Immun. 2015;3:7–12.
   Google Scholar
• Miyaji EN, Oliveira ML, Carvalho E, et al. Serotype-independent pneumococcal vaccines. Cell Mol Life Sci. 2013;70:3303–3326.
   PubMed Web of Science ®Google Scholar